1.Shekhtman L, Cotler S, Ploss A, Dahari H. Mathematical modeling suggests that entry-inhibitor bulevirtide may interfere with hepatitis D virus clearance from circulation. J Hepatol. 2022;76(5):1229–1231. PMCID: PMC9018506 Reference Link
1.Winer B, Shirvani-Dastgerdi E, Bram Y, Sellau J, Low B, Johnson H, Huang T, Hrebikova G, Heller B, Sharon Y, Giersch K, Gerges S, Seneca K, Pais M-A, Frankel A, Chiriboga L, Cullen J, Nahass R, Lutgehetmann M, Toettcher J, Wiles M, Schwartz R, Ploss A. Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection. Sci Transl Med. 2018;10(447). PMCID: PMC6337727 Reference Link
1.Fernández J, Webb C, Rouzard K, Healy J, Tamura M, Voronkov M, Huber K, Stock J, Stock M, Gordon J, Pérez E. SIG1459: A novel phytyl-cysteine derived TLR2 modulator with in vitro and clinical anti-acne activity. Exp Dermatol. 2018;27(9):993–999. PMID: 29797368 Reference Link
1.Fernández J, Webb C, Rouzard K, Voronkov M, Huber K, Stock J, Stock M, Gordon J, Pérez E. N-Acetylglutaminoyl-S-farnesyl-L-cysteine (SIG-1191): an anti-inflammatory molecule that increases the expression of the aquaglyceroporin, aquaporin-3, in human keratinocytes. Arch Dermatol Res. 2017;309(2):103–110. PMCID: PMC5309294 Reference Link
